Physician profile
Michael D Byrd
NPI 1255094678
$3,212.86
in general payments reported to CMS, 2019-2025
10 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.84 · 2022: $717 · 2023: $517 · 2024: $648 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,475.75 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,299.49 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $675.24 | 2022-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $286.51 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $236.35 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $224.99 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $184.56 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $94.83 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.34 | 2022-2025 | Caplyta |
| Alkermes, INC. | $68.98 | 2023-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $63.57 | 2022-2025 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.